New hope for advanced cancers: drug shows promise in shrinking tumors
NCT ID NCT02628067
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This study tests a drug called pembrolizumab in about 1,600 people with advanced solid tumors (like anal, bile duct, or endometrial cancer) that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the tumors. Participants receive pembrolizumab and are monitored for tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.